Review of Negative Prostate Biopsies After Adenocarcinoma Diagnosis
Author Information
Author(s): Jay Patel, Lester J. Layfield
Primary Institution: University of Utah School of Medicine
Hypothesis
Can a quality assurance program improve the detection of false negative results in prostate core needle biopsies?
Conclusion
The study found a false negative rate of 0.68% in prostate core needle biopsies, highlighting the importance of quality assurance in pathology.
Supporting Evidence
- Two biopsies initially diagnosed as no evidence of malignancy were later found to contain adenocarcinoma.
- The false negative rate for core biopsy was 0.68%.
- Twenty-one cases showed atypical small acinar proliferations that were not diagnosed as adenocarcinoma.
Takeaway
This study looked at prostate biopsies to see if doctors missed any cancer diagnoses. They found a few cases where cancer was missed, showing that double-checking can help catch mistakes.
Methodology
The study reviewed five years of quality assurance records for prostate core needle biopsies, focusing on cases with prior negative results.
Potential Biases
The false negative diagnoses were made by junior pathologists, which may introduce bias in the results.
Limitations
The study only included cases from one institution, which may limit the generalizability of the findings.
Participant Demographics
Patients included in the study had prior prostate biopsies, with some diagnosed with adenocarcinoma and others with benign conditions.
Want to read the original?
Access the complete publication on the publisher's website